Suggested Remit: To appraise the clinical and cost effectiveness of nivolumab with ipilimumab within its marketing authorisation for untreated unresectable malignant pleural mesothelioma.
 
Status In progress
Process STA 2018
ID number 1609

Provisional Schedule

Expected publication 23 June 2021

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 September 2019 The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late July- 2020 when we will write to you about how you can get involved.
06 August 2019 - 04 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 May 2019 In progress, Referred 31 July 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance